|
HU222249B1
(hu)
*
|
1991-03-08 |
2003-05-28 |
Amylin Pharmaceuticals Inc. |
Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
|
|
WO1995007098A1
(en)
*
|
1993-09-07 |
1995-03-16 |
Amylin Pharmaceuticals, Inc. |
Methods for regulating gastrointestinal motility
|
|
US6143718A
(en)
*
|
1995-06-07 |
2000-11-07 |
Amylin Pharmaceuticals, Inc. |
Treatment of Type II diabetes mellutis with amylin agonists
|
|
US7312196B2
(en)
|
1997-01-08 |
2007-12-25 |
Amylin Pharmaceuticals, Inc. |
Formulations for amylin agonist peptides
|
|
US6410511B2
(en)
|
1997-01-08 |
2002-06-25 |
Amylin Pharmaceuticals, Inc. |
Formulations for amylin agonist peptides
|
|
US7101853B2
(en)
*
|
1997-05-06 |
2006-09-05 |
Amylin Pharmaceuticals, Inc. |
Method for treating or preventing gastritis using amylin or amylin agonists
|
|
US7910548B2
(en)
*
|
1997-06-06 |
2011-03-22 |
Amylin Pharmaceuticals, Inc. |
Methods for treating obesity
|
|
ES2316161T3
(es)
*
|
1998-01-09 |
2009-04-01 |
Amylin Pharmaceuticals, Inc. |
Formulaciones para peptidos agonistas de amilina con insulina.
|
|
US6087334A
(en)
*
|
1998-08-21 |
2000-07-11 |
Amylin Pharmaceuticals, Inc. |
Anti-diabetic peptides
|
|
EP1474164B1
(en)
*
|
2002-01-08 |
2008-10-29 |
Amylin Pharmaceuticals, Inc. |
Use of amylin, amylin analogs and amylin derivatives to treat dyslipidemia and triglyceridemia
|
|
JP4579681B2
(ja)
*
|
2002-07-09 |
2010-11-10 |
ブリストル−マイヤーズ スクイブ カンパニー |
抗糖尿病薬および抗肥満薬として有用な置換ヘテロシクロ誘導体および方法
|
|
MXPA05012278A
(es)
*
|
2003-05-14 |
2006-02-10 |
Emisphere Tech Inc |
Composiciones para suministrar peptido yy y combatientes pyy.
|
|
WO2005014022A1
(en)
*
|
2003-07-16 |
2005-02-17 |
Develogen Aktiengesellschaft |
Use of pleitrophin for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
|
|
RU2385878C2
(ru)
|
2004-02-11 |
2010-04-10 |
Амилин Фармасьютикалз, Инк. |
Пептид, обладающий свойствами амилина (варианты), и его применение (варианты)
|
|
BRPI0506793A
(pt)
*
|
2004-02-20 |
2007-05-22 |
Rinat Neuroscience Corp |
métodos de tratamento de obesidade ou diabetes com o uso de nt-4/5
|
|
US7399744B2
(en)
*
|
2004-03-04 |
2008-07-15 |
Amylin Pharmaceuticals, Inc. |
Methods for affecting body composition
|
|
WO2006099288A2
(en)
*
|
2005-03-11 |
2006-09-21 |
Indevus Pharmaceuticals, Inc. |
Controlled release formulations of octreotide
|
|
US7759312B2
(en)
*
|
2005-03-11 |
2010-07-20 |
Endo Pharmaceuticals Solutions Inc. |
Delivery of dry formulations of octreotide
|
|
JP2009525319A
(ja)
*
|
2006-02-02 |
2009-07-09 |
ライナット ニューロサイエンス コーポレイション |
ｔｒｋＢアンタゴニストを投与することにより肥満を治療する方法
|
|
AU2007210862A1
(en)
*
|
2006-02-02 |
2007-08-09 |
Rinat Neuroscience Corp. |
Methods for treating unwanted weight loss or eating disorders by administering a trkB agonist
|
|
CA2672750A1
(en)
*
|
2006-12-20 |
2008-07-03 |
Rinat Neuroscience Corporation |
Trkb agonists for treating autoimmune disorders
|
|
EP2219664A1
(en)
*
|
2007-11-14 |
2010-08-25 |
Amylin Pharmaceuticals, Inc. |
Methods for treating obesity and obesity related diseases and disorders
|
|
US8071537B2
(en)
*
|
2008-06-25 |
2011-12-06 |
Endo Pharmaceuticals Solutions Inc. |
Implantable device for the sustained release of a polypeptide
|
|
EP2317975B1
(en)
|
2008-06-25 |
2016-04-13 |
Endo Pharmaceuticals Solutions Inc. |
Octreotide implant having a release agent
|
|
PT3228320T
(pt)
|
2008-10-17 |
2020-03-26 |
Sanofi Aventis Deutschland |
Combinação de uma insulina e de um agonista do glp-1
|
|
JP2009149684A
(ja)
*
|
2009-03-11 |
2009-07-09 |
Amylin Pharmaceut Inc |
アミリン作動薬ペプチド用製剤
|
|
EP2405934B1
(en)
*
|
2009-03-12 |
2014-03-26 |
Nordic Bioscience A/S |
Treatment of diabetes and metabolic syndrome
|
|
US20110118178A1
(en)
*
|
2009-11-13 |
2011-05-19 |
Sanofi-Aventis Deutschland Gmbh |
Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin
|
|
JP5832439B2
(ja)
|
2009-11-13 |
2015-12-16 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
Ｇｌｐ−１アゴニスト、インスリン及びメチオニンを含む薬学的組成物
|
|
SG10201500871TA
(en)
|
2009-11-13 |
2015-04-29 |
Sanofi Aventis Deutschland |
Pharmaceutical composition comprising a glp-1 agonist and methionine
|
|
US20110118180A1
(en)
*
|
2009-11-13 |
2011-05-19 |
Sanofi-Aventis Deutschland Gmbh |
Method of treatment of diabetes type 2 comprising add-on therapy to metformin
|
|
CN103179978A
(zh)
|
2010-08-30 |
2013-06-26 |
赛诺菲-安万特德国有限公司 |
Ave0010用于制造供治疗2型糖尿病用的药物的用途
|
|
US9821032B2
(en)
|
2011-05-13 |
2017-11-21 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
|
|
JP6367115B2
(ja)
|
2011-08-29 |
2018-08-01 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
２型糖尿病患者の血糖コントロールに使用する組合せ医薬
|
|
TWI559929B
(en)
|
2011-09-01 |
2016-12-01 |
Sanofi Aventis Deutschland |
Pharmaceutical composition for use in the treatment of a neurodegenerative disease
|
|
BR102013017626A2
(pt)
*
|
2013-06-14 |
2015-02-10 |
Univ Rio De Janeiro |
Bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, uso de bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, composições farmacêuticas de baixa toxicidade, adjuvante para a prevenção ou tratamento das doenças, medicamento, método de tratamento ou prevenção de doenças.
|
|
CN106687474A
(zh)
*
|
2014-09-04 |
2017-05-17 |
诺和诺德股份有限公司 |
新型胰淀素和降钙素受体激动剂
|
|
CN107206058A
(zh)
|
2014-12-12 |
2017-09-26 |
赛诺菲-安万特德国有限公司 |
甘精胰岛素/利西拉来固定比率配制剂
|
|
TWI748945B
(zh)
|
2015-03-13 |
2021-12-11 |
德商賽諾菲阿凡提斯德意志有限公司 |
第２型糖尿病病患治療
|
|
TW201705975A
(zh)
|
2015-03-18 |
2017-02-16 |
賽諾菲阿凡提斯德意志有限公司 |
第２型糖尿病病患之治療
|